liu.seSearch for publications in DiVA
Change search
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • oxford
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf
Benchmarking biomarker-based criteria for Alzheimer's disease: Data from the Swedish Dementia Registry, SveDem.
The Sahlgrenska Academy at the University of Gothenburg, Mölndal, Sweden.
Karolinska Institutet, Stockholm, Sweden; Karolinska University Hospital, Huddinge, Sweden.
The Sahlgrenska Academy at the University of Gothenburg, Mölndal, Sweden.
Lund University, Malmö, Sweden.ORCID iD: 0000-0003-0194-8402
Show others and affiliations
2015 (English)In: Alzheimer's & Dementia: Journal of the Alzheimer's Association, ISSN 1552-5260, E-ISSN 1552-5279, Vol. 11, no 12, p. 1470-1479, article id S1552-5260(15)00185-5Article in journal (Refereed) Published
Abstract [en]

INTRODUCTION: New research guidelines for the diagnosis of Alzheimer's disease (AD) include biomarker evidence of amyloid-β (Aβ) and tau pathology. The aim of this study was to investigate what proportion of AD patients diagnosed in clinical routine in Sweden that had an AD-indicative cerebrospinal fluid (CSF) biomarker profile.

METHODS: By cross-referencing a laboratory database with the Swedish Dementia Registry (SveDem), 2357 patients with data on CSF Aβ and tau biomarkers and a clinical diagnosis of AD with dementia were acquired.

RESULTS: Altogether, 77.2% had pathologic Aβ42 and total tau or phosphorylated tau in CSF. These results were stable across age groups. Female sex and low mini-mental state examination score increased the likelihood of pathologic biomarkers.

DISCUSSION: About a quarter of clinically diagnosed AD patients did not have an AD-indicative CSF biomarker profile. This discrepancy may partly reflect incorrect (false positive) clinical diagnosis or a lack in sensitivity of the biomarker assays.

Place, publisher, year, edition, pages
Elsevier, 2015. Vol. 11, no 12, p. 1470-1479, article id S1552-5260(15)00185-5
Keywords [en]
Alzheimer's disease, Biomarkers, Cerebrospinal fluid, Diagnosis, Diagnostic criteria
National Category
Geriatrics Neurology
Identifiers
URN: urn:nbn:se:liu:diva-162692DOI: 10.1016/j.jalz.2015.04.007ISI: 000366721600008PubMedID: 26079415Scopus ID: 2-s2.0-84949827682OAI: oai:DiVA.org:liu-162692DiVA, id: diva2:1379229
Available from: 2019-12-16 Created: 2019-12-16 Last updated: 2024-05-02Bibliographically approved

Open Access in DiVA

No full text in DiVA

Other links

Publisher's full textPubMedScopus

Search in DiVA

By author/editor
Nägga, Katarina
In the same journal
Alzheimer's & Dementia: Journal of the Alzheimer's Association
GeriatricsNeurology

Search outside of DiVA

GoogleGoogle Scholar

doi
pubmed
urn-nbn

Altmetric score

doi
pubmed
urn-nbn
Total: 37 hits
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • oxford
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf